Webcast

The live webinar ran on Wednesday 16th November 2022

12:00-13:00 GMT
13:00-14:00 CET
21:00-22:00 JST

Welcome

Despite a wave of new therapies, glycemic control is still inadequate globally.

There are two common reasons for suboptimal glycemic control: firstly, low adherence to medication by the patient and, secondly, the clinician’s failure to initiate or intensify glucose-lowering therapy when it could provide clinical benefit, known as clinical inertia.

Clinical inertia is common, affecting up to 50% of patients with type 2 diabetes. There are many causes of clinical inertia including a lack of confidence in the appropriate use of newer therapies, non-adherence to updated guidelines, and management plans being performed in a traditional, linear way with inefficient communication across specialties and with the patient.

This discussion-based webinar aims to address the causes of clinical inertia and look at strategies to overcome and avoid it.

Clinical experts

Program director and Chair

Melanie Davies (UK)
Professor of Diabetes Medicine, University of Leicester, Diabetes Research Centre

Bio

Paola Fioretto (Italy)
Professor of Medicine, Department of Medicine, University of Padova

Bio

Francesc Xavier Cos (Spain)
Innovation and research officer; University Professor; Primary Care Specialist; Institut Català de la Salut

Bio

Full webcast

CHAPTER 1: Introduction and Causes and consequences of global clinical inertia in type 2 diabetes

CHAPTER 2: Acknowledging and understanding clinical inertia: where are we going wrong? Case-based discussion

CHAPTER 3: How can we work together to avoid clinical inertia? Panel discussion and audience Q&A

Click here to complete the evaluation form

Target audience

This independent educational program is suitable for endocrinologists, diabetologists and primary care practitioners worldwide who provide front-line care of patients with diabetes.

Learning objectives

Following completion of this independent educational program, you will be able to:

Discuss the causes of therapeutic inertia in type 2 diabetes and ways to overcome it
Adapt management plans to address cardiometabolic risks independent of HbA1c through a detailed understanding of the CVOT data and up-to-date guidelines
Debate initiatives to improve multidisciplinary working and shared decision making in type 2 diabetes care

Accreditation

In support of improving patient care, this activity has been planned and implemented by HMP Education and Springer Healthcare IME. HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

HMP Education designates this webinar for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Webinar took place on 16th November 2022
Webcast publication date: 9th December 2022
Expiration date: 9th December 2023

Disclosures

In addition to the expert faculty, Springer Healthcare IME planners and staff include Rachel Goddard, James Hutton, and Rebecca Cox. The Planning Committee have no financial relationships to disclose.

Funding

This activity is supported by an educational grant from Lilly.

Endorsement

PCDE endorses and supports the live webinar and on-demand webcast “Overcoming clinical inertia in T2D” on 16 November 2022.

moc/regnirps//EMI

Springer Healthcare IME, The Campus, 4 Crinan Street, London, N1 9XW, UK

Melanie Davies

Professor of Diabetes Medicine, University of Leicester, Diabetes Research Centre

Melanie Davies is a clinician with over 25 years’ experience working as a diabetologist and physician, and since 2006 is a Professor of Diabetes Medicine at the University of Leicester, in the UK. She is a National Institute of Health Research (NIHR) Senior Investigator, one of only a handful in diabetes in the UK, Director of the NIHR Leicester-Loughborough Diet, Lifestyle and Physical Activity Biomedical Research Unit, Director of a Clinical Trial Unit, Lead for Division 2 of the Clinical Research Network East Midlands and Principal Investigator on a number of large global studies in the field of diabetes, obesity and cardiovascular disease.

Professor Davies is the global PI on the SCALE Obesity trial, a large multinational study investigating management of obesity with GLP-1 analogue.

She has had more than 180 peer review publications and has been awarded over £30,000,000 of external reviewed grant funding.

Disclosures

Honoraria or consultation fees - Boehringer Ingelheim, Lilly, Novo Nordisk, Sanofi, AstraZeneca, Janssen, Lexicon, Pfizer, ShouTi Pharma Inc
Participation in a company sponsored speaker bureau - Napp Pharmaceuticals, Novartis and Takeda Pharmaceuticals International Inc

Paola Fioretto

Professor of Medicine, Department of Medicine, University of Padova

Paola Fioretto is Professor in Medicine at the University of Padova, Italy. She started her research on renal physiology in diabetes and, during her PostDoc Research Fellowship at the University of Minnesota, she devoted her interest to renal structure and ultrastructure in diabetes. Among her contributions to the understanding of diabetic kidney disease are the descriptions of the heterogeneity in the structural lesions underlying renal dysfunction in type 2 diabetes, and of reversal of established diabetic glomerulopathy lesions in patients with type 1 diabetes after pancreas transplantation.

Professor Fioretto’s research interest includes the effects of glucose-lowering therapies on the development and progression of diabetic kidney disease.

She has received several awards, including the Albert Renold award from the EASD (European Association for the Study of Diabetes), a Career Development Award from JDFI, the Morgagni Young Investigator Award, the Novartis Young Investigator, the Italian Society of Diabetology Award, and the Golgi Prize from the EASD. She has been Vice President of the EASD (2014-2017), and President of the European Diabetic Nephropathy Study Group of the EASD (2005-2007). She has published over 190 papers and 30 book chapters.

Disclosures

Honoraria or consultation fees - AstraZeneca, Boehringer Ingelheim, Lilly, Mundipharma, Bayer, Novo.

Francesc Xavier Cos

Innovation and research officer; University Professor; Primary Care Specialist; Institut Català de la Salut

Francesc Xavier Cos is a GP in Sant Martí Primary Health Centres and innovation and research officer at Institut Català de la Salut, Barcelona ( Spain). His main areas of interest are Innovation, research and Education in health His background in Primary Care has special relevance in the field of Diabetes.

Dr Cos is a member and European representative in Diabetes and Endocrine disorders of the Primary Care University Research Institute Jordi Gol, where he is an active member in 2 working groups: Diabetes Prevention and Epidemiological Database analysis. He started his activities on Diabetes at GEDAPS “Primary Care Diabetes Study Group” in 1997.

He has worked on many institutional projects for the Catalonian Health Department, and is regularly invited to participate in national and international ( LATAM, Middle East,...) meetings to lecture on Diabetes in Primary Care, to develop and conduct educational activities and to develop.

Dr Cos works on various research projects in Diabetes prevention and has been involved in many randomized clinical trials. He is also involved as an Associate Professor at the medicine department of the Universitat Autonoma de Barcelona since 2009 and is an associate editor of the Primary Care Diabetes journal. In 2009 he was elected as vice chairman of the Primary Care Diabetes Europe and in February 2016 as Chairman elect. In February 2017 he was appointed as Chairman of PCDE for 4 years.

Disclosures

Grants/research support - AstraZeneca, Novartis, SANOFI, Boehringer Ingelheim
Honoraria or consultation fees - AstraZeneca, ABBOTT, Boehringer Ingelheim, Lilly, Novartis, Novo Nordisk and Sanofi Diabetes, Sanofi Pasteur, Esteve
Participation in a company sponsored speaker bureau - AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, Novo Nordisk, Sanofi Diabetes, Sanofi Pasteur